Suggested remit: To appraise the clinical and cost effectiveness of fezolinetant within its marketing authorisation for treating vasomotor symptoms associated with the menopause.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
5071
|
Provisional Schedule
| Committee meeting: 1 |
04 March 2025 |
| Expected publication |
21 May 2025 |
Project Team
| Project lead |
Jennifer Upton |
Email enquiries
|
Date
|
Update
|
|
30 July 2024
|
Invitation to participate |
|
20 June 2024
|
Draft scope documents |
|
12 October 2023
|
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late July 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
24 July 2023
|
Stakeholder workshop |
|
25 May 2023 - 23 June 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5071 |
|
25 May 2023
|
In progress. Scoping commencing |
|
25 November 2022
|
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Fezolinetant for untreated vasomotor symptoms associated with the menopause.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early December 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
07 June 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual